NRXP · NRX Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Javitt Daniel C. 10% Owner | ▼ Sell | Open Market | 9,634,793 Shares held | 11/30/2022 | View profile |
| Hurvitz Chaim Director | ▲ Buy | Open Market | 570,000 Shares held | 8/30/2023 | View profile |
| Gorovitz Aaron | ▲ Buy | Open Market | 105,000 Shares held | 8/30/2023 | View profile |
| Javitt Jonathan C Chief Scientist | ▲ Buy | Open Market | 84,634 Shares held | 12/17/2024 | View profile |
| Stephen H. Willard Chief Executive Officer | ▲ Buy | Open Market | 50,000 Shares held | 12/16/2022 | View profile |
| VAN VOORHEES SETH CHIEF FINANCIAL OFFICER | ▲ Buy | Open Market | 46,337 Shares held | 12/16/2022 | View profile |
| Daigneault Alessandra General Counsel & Secretary | ▲ Buy | Option Exercise | 31,584 Shares held | 9/2/2021 | View profile |
| Besthof Robert Chief Comm. & Patient Officer | ▼ Sell | Open Market | 23,710 Shares held | 9/15/2021 | View profile |
| Herbert Raymond McMaster Director | ▲ Buy | Option Exercise | 18,300 Shares held | 8/26/2021 | View profile |
| Flynn Patrick John | ▲ Buy | Open Market | 1,750 Shares held | 11/28/2022 | View profile |
Transaction History
| Javitt Jonathan C | ▲ Buy | Open Market | 40,000 | $47K | 12/17/2024 |
| Gorovitz Aaron | ▲ Buy | Open Market | 35,000 | $11K | 8/30/2023 |
| Hurvitz Chaim | ▲ Buy | Open Market | 70,000 | $20K | 8/30/2023 |
| Javitt Jonathan C | ▲ Buy | Open Market | 100,000 | $33K | 8/23/2023 |
| Javitt Jonathan C | ▲ Buy | Open Market | 200,000 | $64K | 8/22/2023 |
| Stephen H. Willard | ▲ Buy | Open Market | 50,000 | $59K | 12/16/2022 |
| VAN VOORHEES SETH | ▲ Buy | Open Market | 30,000 | $33K | 12/16/2022 |
| Javitt Jonathan C | ▼ Sell | Open Market | 400,000 | $400K | 12/7/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 8,441 | $13K | 11/30/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 13,730 | $21K | 11/29/2022 |
| Flynn Patrick John | ▲ Buy | Open Market | 2,500 | $3K | 11/28/2022 |
| Flynn Patrick John | ▲ Buy | Open Market | 2,500 | $3K | 11/28/2022 |
| Flynn Patrick John | ▲ Buy | Open Market | 2,500 | $3K | 11/28/2022 |
| Flynn Patrick John | ▲ Buy | Open Market | 2,500 | $3K | 11/28/2022 |
| Flynn Patrick John | ▲ Buy | Open Market | 1,750 | $2K | 11/28/2022 |
| VAN VOORHEES SETH | ▲ Buy | Open Market | 8,716 | $10K | 11/25/2022 |
| VAN VOORHEES SETH | ▲ Buy | Open Market | 600 | $660 | 11/25/2022 |
| VAN VOORHEES SETH | ▲ Buy | Open Market | 7,021 | $8K | 11/25/2022 |
| Hurvitz Chaim | ▲ Buy | Open Market | 40,408 | $44K | 11/18/2022 |
| Hurvitz Chaim | ▲ Buy | Open Market | 171,780 | $186K | 11/17/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 33,018 | $35K | 11/17/2022 |
| Hurvitz Chaim | ▲ Buy | Open Market | 287,812 | $285K | 11/16/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 133,719 | $136K | 11/16/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 49,200 | $50K | 11/11/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 784,063 | $791K | 7/29/2022 |
| Javitt Daniel C. | ▼ Sell | Gift | 2,000,000 | $0 | 7/1/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 86,459 | $56K | 6/7/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 115,657 | $77K | 6/6/2022 |
| Javitt Daniel C. | ▼ Sell | Open Market | 243,596 | $171K | 6/3/2022 |
| Javitt Jonathan C | ▲ Buy | Open Market | 100,000 | $5.8M | 6/1/2022 |
| Besthof Robert | ▼ Sell | Open Market | 40,000 | $470K | 9/15/2021 |
| Daigneault Alessandra | ▲ Buy | Option Exercise | 18,420 | $57K | 9/2/2021 |
| Daigneault Alessandra | ▲ Buy | Option Exercise | 13,164 | $40K | 9/2/2021 |
| Herbert Raymond McMaster | ▲ Buy | Option Exercise | 18,300 | $41K | 8/26/2021 |
| Daigneault Alessandra | ▼ Sell | Open Market | 33,715 | $442K | 8/23/2021 |
| Daigneault Alessandra | ▲ Buy | Option Exercise | 27,395 | $84K | 8/19/2021 |
| Besthof Robert | ▲ Buy | Option Exercise | 63,710 | $13K | 8/16/2021 |
| Javitt Daniel C. | ▼ Sell | Gift | 434,594 | — | 7/16/2021 |
| Javitt Daniel C. | ▼ Sell | Gift | 434,594 | — | 7/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.